Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Viral Hepatitis
How do you explain the additional risks that a transplant recipient may carry by pursuing a hepatitis C positive organ if they are negative?
Related Questions
What kind of monitoring do you choose in patients at risk for reactivation of hepatitis B who are on immunosuppression?
In what scenarios do you defer treatment of a patient's hepatitis C if they are undergoing liver transplant evaluation?
All things being equal, what patient factors are you looking at in the selection of TAF or TDF in the management of hepatitis B?
What role is there for the use of ursodiol in relapsing hepatitis A for management of liver enzyme abnormalities and patient symptoms?
What is your approach to a patient with an elevated alkaline phosphatase level, but negative PBC serologies and normal biliary imaging?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
What are your biggest takeaways from the MASH-TAG 2025 conference?
For how long would you treat a patient with latent TB before allowing them to proceed with a liver transplant?
How do you approach a patient with discordant Fibroscan and serologic testing for fibrosis?
Is there benefit to aggressively treating hemochromatosis in a patient who has already progressed to cirrhosis at the time of diagnosis?
